Welcome to our dedicated page for Design Therapeutics news (Ticker: DSGN), a resource for investors and traders seeking the latest updates and insights on Design Therapeutics stock.
Design Therapeutics, Inc. reports news about its clinical-stage biotechnology business and its GeneTAC® platform for serious degenerative genetic diseases. The company develops gene targeted chimera small molecules designed to modulate expression of disease-causing genes, with programs that include DT-216P2 for Friedreich ataxia, DT-168 for Fuchs endothelial corneal dystrophy, DT-818 for myotonic dystrophy type 1, and a Huntington’s disease program.
Recurring updates cover financial results, cash resources for pipeline execution, clinical program progress, regulatory clearances, preclinical development, investor conference participation, and board or committee changes. Company announcements frequently connect portfolio milestones with the underlying GeneTAC approach and the therapeutic areas addressed by its genomic medicine programs.
Design Therapeutics has priced its initial public offering (IPO) at $20.00 per share, aiming to raise $240 million with 12 million shares being offered. The IPO will commence trading on the Nasdaq under the ticker symbol DSGN on March 26, 2021, and is expected to close on March 30, 2021. A 30-day option for underwriters to purchase an additional 1.8 million shares is also granted. Goldman Sachs, SVB Leerink, and Piper Sandler are managing the offering.